Thomas Schinecker, Roche CEO (ddp images/Sipa USA/Sipa via AP Images)
July 25, 2024 07:16 AM EDTUpdated 07:31 AM
R&D
Pharma

Roche cuts two more TIG­IT tri­als, plans ac­cel­er­at­ed time­line for obe­si­ty drugs

Amber Tong

A year in­to Roche’s com­pre­hen­sive port­fo­lio re­view, the Swiss phar­ma said it has now tak­en out 25% of new drug can­di­dates from its pipeline. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times